|
|
|
|
||
Re: overly optimisticVery true but nexavar achieved $800 million revenue in a prior year. HCC approval would have to happen to get anything in a similar ballpark is my guess but OM approval might be good for a lot more than currently. I don't know offhand a scientific method if OM approval approaches for guessing price on approval. Other trial progress, orphan prices, offlabel volume, how many months improvement in next phase 3, irrational stock market. sam |
return to message board, top of board |